Implantable construct for architectural control of re-vascularization of ischemic

描述（由申请人提供）：Innolign Biomedical开发了一种植入式产品，该产品使用新型组织工程技术在空间上直接血管化，并将用于治疗缺血性疾病。这项I期STTR提案的目标是确定使用这种新型模板生物材料（称为MicroBridge）治疗心脏缺血的可行性。超过2000万美国人患有缺血性心脏病，估计每年的费用负担超过600亿美元。尽管在挽救冠状动脉循环灌注的血管成形术和搭桥手术方面取得了重大进展，但缺血性心脏病仍然是死亡率和发病率的主要原因。MicroBridge将作为冠状动脉搭桥手术的辅助工具，指导微血管再灌注到单独大动脉搭桥无法到达的缺血区域。该产品由预先指定的网状结构组成，排列整齐的内皮细胞和基质在可生物降解的植入物中。植入后，MicroBridge的结构模板引导新血管从灌注良好的区域快速生长到缺血区域。目的1是测试MicroBridge产品在心脏缺血动物模型中血管化和缺血组织再灌注的能力。目的2是建立MicroBridge产品在特定储存条件下的稳定性。这些研究将为MicroBridge产品作为心脏缺血治疗的进一步发展奠定基础。

DESCRIPTION (provided by applicant): Innolign Biomedical has developed an implantable product using novel tissue engineering technologies that spatially direct vascularization and will use the product in the treatment of ischemic conditions. The goal of this Phase I STTR proposal is to establish the feasibility of using this novel templated biomaterial, termed MicroBridge, to treat cardiac ischemia. More than 20 million Americans suffer from the ischemic heart disease with an estimated cost burden surpassing $60 billion annually. Despite substantial progress in angioplasty and bypass surgery to rescue perfusion to the coronary circulation, ischemic heart disease remains the leading cause of mortality and morbidity. MicroBridge will serve as an adjunct delivered during coronary artery bypass surgery that would direct vascularization in the microvasculature to reperfuse regions of ischemia not reached by large artery bypass alone. The product consists of pre- specified architectures of networks of aligned cords of endothelial cells and matrix within a biodegradable implant. Upon implantation, the architectural template of MicroBridge guides new vessels to rapidly grow from a well perfused region to an ischemic region. The goal of Aim 1 is to test the capability of the MicroBridge product to vascularize and reperfuse ischemic tissue in an animal model of cardiac ischemia. The goal of Aim 2 is to establish the stability of the MicroBridge product under specific storage conditions. These studies will set the stage for further development of the MicroBridge product as a treatment for cardiac ischemia.